Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

645 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Dolutegravir-Based or Low-Dose Efavirenz-Based Regimen for the Treatment of HIV-1.
NAMSAL ANRS 12313 Study Group; Kouanfack C, Mpoudi-Etame M, Omgba Bassega P, Eymard-Duvernay S, Leroy S, Boyer S, Peeters M, Calmy A, Delaporte E. NAMSAL ANRS 12313 Study Group, et al. Among authors: calmy a. N Engl J Med. 2019 Aug 29;381(9):816-826. doi: 10.1056/NEJMoa1904340. Epub 2019 Jul 24. N Engl J Med. 2019. PMID: 31339676 Clinical Trial.
Effectiveness and safety of a generic fixed-dose combination of nevirapine, stavudine, and lamivudine in HIV-1-infected adults in Cameroon: open-label multicentre trial.
Laurent C, Kouanfack C, Koulla-Shiro S, Nkoué N, Bourgeois A, Calmy A, Lactuock B, Nzeusseu V, Mougnutou R, Peytavin G, Liégeois F, Nerrienet E, Tardy M, Peeters M, Andrieux-Meyer I, Zekeng L, Kazatchkine M, Mpoudi-Ngolé E, Delaporte E. Laurent C, et al. Among authors: calmy a. Lancet. 2004 Jul 3-9;364(9428):29-34. doi: 10.1016/S0140-6736(04)16586-0. Lancet. 2004. PMID: 15234853 Clinical Trial.
Adherence to antiretroviral therapy assessed by drug level monitoring and self-report in cameroon.
Kouanfack C, Laurent C, Peytavin G, Ciaffi L, Ngolle M, Nkene YM, Essomba C, Calmy A, Mpoudi-Ngolé E, Delaporte E, Koulla-Shiro S; French National Agency for Research on AIDS 1274 Study Group. Kouanfack C, et al. Among authors: calmy a. J Acquir Immune Defic Syndr. 2008 Jun 1;48(2):216-9. doi: 10.1097/QAI.0b013e3181743955. J Acquir Immune Defic Syndr. 2008. PMID: 18520681 Free article.
Hepatotoxicity and effectiveness of a Nevirapine-based antiretroviral therapy in HIV-infected patients with or without viral hepatitis B or C infection in Cameroon.
Mbougua JB, Laurent C, Kouanfack C, Bourgeois A, Ciaffi L, Calmy A, Gwet H, Koulla-Shiro S, Ducos J, Mpoudi-Ngolé E, Molinari N, Delaporte E. Mbougua JB, et al. Among authors: calmy a. BMC Public Health. 2010 Mar 1;10:105. doi: 10.1186/1471-2458-10-105. BMC Public Health. 2010. PMID: 20193053 Free PMC article.
A randomized crossover study to compare efavirenz and etravirine treatment.
Nguyen A, Calmy A, Delhumeau C, Mercier IK, Cavassini M, Fayet-Mello A, Elzi L, Genné D, Rauch A, Bernasconi E, Hirschel B; Swiss HIV Cohort Study. Nguyen A, et al. Among authors: calmy a. AIDS. 2011 Jan 2;25(1):57-63. doi: 10.1097/QAD.0b013e32833f9f63. AIDS. 2011. PMID: 21076278 Clinical Trial.
Mean CD4 cell count changes in patients failing a first-line antiretroviral therapy in resource-limited settings.
Calmy A, Balestre E, Bonnet F, Boulle A, Sprinz E, Wood R, Delaporte E, Messou E, McIntyre J, El Filali KM, Schechter M, Kumarasamy N, Bangsberg D, McPhail P, Van Der Borght S, Zala C, Egger M, Thiébaut R, Dabis F; T-LINC of IeDEA Collaboration (Asia, South America, East, Southern and West Africa). Calmy A, et al. BMC Infect Dis. 2012 Jun 28;12:147. doi: 10.1186/1471-2334-12-147. BMC Infect Dis. 2012. PMID: 22742573 Free PMC article.
645 results